Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne
Biological and Pharmaceutical Bulletin · 2024
DOI: 10.1248/bpb.b23-00797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Mana Murae und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19, Cholesterol. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
The coronavirus disease 2019 (COVID-19) is caused by the etiological agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19, with the recurrent epidemics of new variants of SARS-CoV-2, remains a global public health problem, and new antivirals are still required. Some cholesterol derivatives, such as 25-hydroxycholesterol, are known to have antiviral activity against a wide range of enveloped and non-enveloped viruses, including SARS-CoV-2. At the entry step of SARS-CoV-2 infection, the viral envelope fuses with the host membrane dependent of viral spike (S) glycoproteins. From the screening of cholesterol derivatives, we found a new compound 26,27-dinorcholest-5-en-24-yne-3β,20-diol (Nat-20(S)-yne) that inhibited the SARS-CoV-2 S protein-dependent membrane fusion in a syncytium formation assay. Nat-20(S)-yne exhibited the inhibitory activities of SARS-CoV-2 pseudovirus entry and intact SARS-CoV-2 infection in a dose-dependent manner. Among the variants of SARS-CoV-2, inhibition of infection by Nat-20(S)-yne was stronger in delta and Wuhan strains, which predominantly invade into cells via fusion at the plasma membrane, than in omicron strains. The interaction between receptor-binding domain of S proteins and host receptor ACE2 was not affected by Nat-20(S)-yne. Unlike 25-hydroxycholesterol, which regulates various steps of cholesterol metabolism, Nat-20(S)-yne inhibited only de novo cholesterol biosynthesis. As a result, plasma membrane cholesterol content was substantially decreased in Nat-20(S)-yne-treated cells, leading to inhibition of SARS-CoV-2 infection. Nat-20(S)-yne having a new mechanism of action may be a potential therapeutic candidate for COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases.
- Laboratory of Molecular Targeted Therapy, Faculty of Pharmaceutical Sciences, Tokyo University of Science.
- Department of Pharmaceutical Sciences, Teikyo Heisei University.
- Division of Molecular Interaction, Institute for Genetic Medicine, Hokkaido University Graduate School of Life Science.
- Department of Virology I, National Institute of Infectious Diseases.
- Department of Virology, Toyama Institute of Health.
Zitieren
APA
Murae, M., Sakai, S., Miyata, N., Shimizu, Y., Okemoto-Nakamura, Y., Kishimoto, T., Ogawa, M., Tani, H., Tanaka, K., Noguchi, K., & Fukasawa, M. (2024). Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00797
Vancouver
Murae M, Sakai S, Miyata N, Shimizu Y, Okemoto-Nakamura Y, Kishimoto T, et al. Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b23-00797
BibTeX
@article{Murae2024,
author = {Murae, Mana and Sakai, Shota and Miyata, Non and Shimizu, Yoshimi and Okemoto-Nakamura, Yuko and Kishimoto, Takuma and Ogawa, Motohiko and Tani, Hideki and Tanaka, Kazuma and Noguchi, Kohji and Fukasawa, Masayoshi},
title = {Inhibition Mechanism of SARS-CoV-2 Infection by a Cholesterol Derivative, Nat-20(S)-yne},
journal = {Biological and Pharmaceutical Bulletin},
year = {2024},
doi = {10.1248/bpb.b23-00797}
}
EUVIMED